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Abstract: The role of endoplasmic reticulum stress and the unfolded protein response (UPR) in
cholestatic liver disease and fibrosis is not fully unraveled. Tauroursodeoxycholic acid (TUDCA),
a hydrophilic bile acid, has been shown to reduce endoplasmic reticulum (ER) stress and counteract
apoptosis in different pathologies. We aimed to investigate the therapeutic potential of TUDCA
in experimental secondary biliary liver fibrosis in mice, induced by common bile duct ligation.
The kinetics of the hepatic UPR and apoptosis during the development of biliary fibrosis was
studied by measuring markers at six different timepoints post-surgery by qPCR and Western
blot. Next, we investigated the therapeutic potential of TUDCA, 10 mg/kg/day in drinking
water, on liver damage (AST/ALT levels) and fibrosis (Sirius red-staining), in both a preventive
and therapeutic setting. Common bile duct ligation resulted in the increased protein expression
of CCAAT/enhancer-binding protein homologous protein (CHOP) at all timepoints, along with
upregulation of pro-apoptotic caspase 3 and 12, tumor necrosis factor receptor superfamily, member
1A (TNFRsf1a) and Fas-Associated protein with Death Domain (FADD) expression. Treatment with
TUDCA led to a significant reduction of liver fibrosis, accompanied by a slight reduction of liver
damage, decreased hepatic protein expression of CHOP and reduced gene and protein expression of
pro-apoptotic markers. These data indicate that TUDCA exerts a beneficial effect on liver fibrosis in
a model of cholestatic liver disease, and suggest that this effect might, at least in part, be attributed to
decreased hepatic UPR signaling and apoptotic cell death.
Keywords: liver fibrosis; cirrhosis; tauroursodeoxycholic acid; endoplasmic reticulum stress;
unfolded protein response; apoptosis; cell death
1. Introduction
Cholestatic liver disease includes a spectrum of hepatobiliary pathologies and is characterized
by impaired hepatobiliary production or excretion of bile, which causes biliary stasis and retention
of bile acids [1]. Chronic cholestasis, caused by genetic defects, toxins, mechanical aberrations or
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dysregulation of the immune system, leads to increased bile acid accumulation, which induces liver
damage and cell death via diverse mechanisms [2]. Hydrophobic bile acids are cytotoxic due to their
detergent action on lipid components and potential to induce oxidative stress and mitochondrial
dysfunction which eventually results in hepatocyte and cholangiocyte death [3]. This process, along
with apoptotic debris and paracrine stimulation by neighboring cells, among many inducing factors,
causes hepatic stellate cell activation, initiating progressive fibrosis [4,5].
Accumulation of bile acids is known to induce stress to the endoplasmic reticulum (ER) [6–9].
ER stress refers to a state triggered by a disruption of ER homeostasis, which results in the accumulation
of unfolded proteins within the ER lumen [10]. There are three transmembrane ER stress sensors:
the inositol-requiring enzyme 1 (IRE1), the activating transcription factor 6 (ATF6) and the PKR-like
endoplasmic reticulum kinase (PERK). In normal conditions, these ER stress receptors are maintained
in an inactive state through association with the ER chaperone glucose-regulated protein, 78 kDa
(Grp78 or BiP). During ER stress, the accumulation of unfolded proteins triggers the dissociation of
BiP, releasing the sensors and activating the IRE1, ATF6 and PERK pathways. This signaling is referred
to as the unfolded protein response (UPR). The UPR functions as an adaptive mechanism, aiming to
restore cellular homeostasis. However, if ER stress sustains, the UPR switches to ER stress-induced cell
death signaling, which is characterized by the involvement of the pro-apoptotic transcription factor
CCAAT/enhancer-binding protein homologous protein (CHOP) [11]. CHOP-mediated apoptotic cell
death has been reported in both in vitro and in vivo experiments, as well as in acute and chronic liver
pathologies such as acetaminophen overdose, non-alcoholic steatohepatitis and cholestasis [6,12–14].
However, the therapeutic potential to inhibit UPR-mediated liver damage following cholestasis in
the evolution towards chronic liver disease and fibrosis has not been fully explored. In this context,
we were interested in the hydrophilic bile acid tauroursodeoxycholic acid (TUDCA), which is known
for its ER stress-reducing and anti-apoptotic capacities [15–27].
Tauroursodeoxycholic acid is the taurine-conjugated form of ursodeoxycholic acid (UDCA),
which is FDA approved for the treatment of cholestatic liver disease, including primary biliary cirrhosis,
and has no major adverse effects [28]. UDCA’s effectiveness is limited by its poor bioavailability,
which can be improved by taurine conjugation. It has been demonstrated that TUDCA binds to the
hydrophobic regions of proteins, thereby preventing protein aggregation and reducing ER stress and
related apoptosis [29]. In addition, recently, the activation of CHOP was shown to stimulate the
transcription of pro-caspase 1 and 11, which become activated upon cleavage and activation by NLRP3,
the most important inflammasome [14].
In this study, we explored the hepatic UPR and cell death signature in time during the initiation
and progression of cholestasis-induced liver fibrosis in mice, and investigated whether modulating
these processes with TUDCA has a beneficial effect on liver damage and fibrosis. We found that the
UPR response is activated after common bile duct ligation (CBDL) and that preventive and therapeutic
treatment with TUDCA results in a significant reduction of liver fibrosis, which was associated with
decreased expression of UPR and pro-apoptotic markers.
2. Results
2.1. Common Bile Duct Ligation Activates the Hepatic Unfolded Protein Response
We first investigated the UPR signature during the onset and progression of CBDL-induced liver
fibrosis by analyzing mRNA or protein expression of different UPR markers. Mice were sacrificed on
a weekly basis, starting from week 1 until week 6 after surgical induction. The mRNA levels of BiP
were increased 6 weeks post CBDL. Activating transcription factor 4 (ATF4) and spliced X-box binding
protein 1 (XBP1s) mRNA transcripts were not increased at any point following CBDL. Unspliced
XBP1 (XBP1u) levels showed an increase at week 3 and growth arrest and DNA damage-inducible
protein (GADD34) mRNA levels were significantly upregulated from week 3 until week 6 post-CBDL
(Figure 1a). No increase in GADD34, ATF4 or phosphorylated eukaryotic initiation factor 2 α (peIF2α)
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protein levels could be detected, however, a gradual increase of CHOP expression in CBDL mice
was seen on Western blot analysis starting at week 1 onwards to week 6 (Figure 1b). While c-Jun
N-terminal kinase (JNK) activation is associated with apoptosis, we could not detect an increase in
JNK phosphorylation in the time after CBDL (Figure 1b).
Int. J. Mol. Sci. 2017, 18, 214  3 of 13 
 
While c-Jun N-terminal kinase (JNK) activation is associated with apoptosis, we could not detect an 
increase in JNK phosphorylation in the time after CBDL (Figure 1b). 
 
Figure 1. Common bile duct ligation (CBDL) activates the unfolded protein response. (a) Real-time 
quantitative polymerase chain reaction analysis of growth arrest and DNA damage-inducible protein 
(GADD34), unspliced X-box binding protein 1 (XBP1u) and spliced XBP1 (XBP1s); (b) Western blot 
and quantification of CCAAT/enhancer-binding protein homologous protein (CHOP), GADD34, 
activating transcription factor 4 (ATF4), (phosphorylated) eukaryotic initiation factor 2 alpha 
(p)eIF2α, and c-Jun N-terminal kinase (p)JNK on whole liver lysates. Results are representative of all 
samples: samples of three to five mice were mixed for blotting and two different pools of the CBDL 
samples were blotted. β-Tubulin and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) were 
used for normalization. Data are presented as mean ± SD. * p < 0.05, ** p < 0.01. 
Figure 1. Common bile duct ligation (CBDL) activates the unfolded protein response. (a) Real-time
quantitative polymerase chain reaction analysis of growth arrest and DNA damage-inducible protein
(GADD34), unspliced X-box binding protein 1 (XBP1u) and spliced XBP1 (XBP1s); (b) Western blot and
quantificatio of CCAAT/enhancer-binding protein homologous protein (CHOP), GADD34, activating
transcription f ctor 4 (ATF4), (phosphorylated) eukaryotic initi ion factor 2 alpha (p)eIF2α, and c-Jun
N-terminal kin se (p)JNK on whole liv r lysates. Results are representative of all samples: samples of
three to five mice were mixed for blotting and two different pools of the CBDL samples were blotted.
β-Tubulin and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) were used for normalization.
Data are presented as mean ± SD. * p < 0.05, ** p < 0.01.
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2.2. CBDL Induces a Pro-Apoptotic Response
Since previous reports described the involvement of apoptosis in cholestatic liver damage and
as CBDL was associated with induction of the pro-apoptotic ER stress marker CHOP in our study,
we evaluated the expression of caspase 3, executor of both the intrinsic and extrinsic apoptotic pathway,
ER stress-induced caspase 12, and tumor necrosis factor receptor superfamily member 1a (TNFRsf1a)
and Fas-Associated protein with Death Domain (FADD), two markers involved in extrinsic apoptotic
cell death. Caspase 3 mRNA expression was significantly upregulated starting at week 1 (with the
exception of weeks 2 and 3), and caspase 12 was significantly increased at all timepoints after CBDL,
compared to sham surgery (Figure 2a). TNFRsf1a and FADD were upregulated at all timepoints in
CBDL mice compared to their matching control group (Figure 2a). Besides apoptosis, the possible
involvement of inflammasome activation, which results in pyroptotic cell death, was assessed by
measuring caspase 1 and nucleotide-binding, leucine-rich repeat and pyrin domains-containing protein
3 (NLRP3) inflammasome levels. Although caspase 1 gene expression was increased from week 3
until week 6 in CBDL mice (Figure 2b), no increase in NLRP3 protein expression was demonstrated
(Figure 2c).
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with Death Domain (FADD); (b) Real time qPCR analysis of caspase 1; (c) Western blot of nucleotide 
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Figure 2. CBDL induces a pro-apoptotic response. (a) Real-time qPCR analysis of caspase 3, caspase 12,
tumor necrosis factor receptor superfamily, member 1A (TNFRsf1a) and Fas-Associated protein with
Death Domain (FADD); (b) Real time qPCR analysis of caspase 1; (c) Western blot of nucleotide binding,
leucine-rich repeat and pyrin domains-containing protein 3 (NLRP3) on whole liver lysates. Western
blot results are representative of all samples: samples of three to five mice were mixed for blotting and
two different pools of the CBDL samples were blotted. Quantification of NLRP3 was normalized to
total protein load. Data are presented as mean ± SD. * p < 0.05, ** p < 0.01, *** p < 0.001.
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2.3. Treatment with TUDCA Reduces the Degree of Liver Fibrosis
As we demonstrated the induction of ER stress and involvement of apoptotic cell death in
this animal model of cholestatic liver disease, we next investigated the therapeutic potential of
TUDCA, which is known for its ER stress-reducing and anti-apoptotic capacities, on the degree
of CBDL-induced liver fibrosis. In a preventive and a therapeutic study, TUDCA was administered
starting one week before and two weeks after surgical induction until the end of the experiments
respectively. As expected, the CBDL procedure resulted in a significant increase in fibrotic area
compared to sham surgery (Figure 3). Importantly, TUDCA treatment, both in the preventive and
the therapeutic setting, led to a significant reduction of liver fibrosis (Figure 3). This was associated
with reduced, however not significantly reduced, liver damage, as reflected by AST and ALT levels
(Table 1).
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Figure 3. Treatment with TUDCA reduces the degree of liver fibrosis: (a) Representative histological
images of livers from a sham mouse, a CBDL control and CBDL mice treated with TUDCA, stained
with Sirius red. Original magnification 100×; (b) Computerized quantification of fibrosis scores
(mean fibrotic area (%) ± SD). * p < 0.05, ** p < 0.01, *** p < 0.001.
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Table 1. ALT and AST levels.
Group Number of Animals ALT AST
sham 6 24.05 ± 5.60 101.20 ± 36.17
sham + TUDCA 7 27.23 ± 8.36 96.43 ± 36.84
CBDL 9 312.3 ± 85.26 *** 505.3 ± 124 ***
CBDL + TUDCA preventive 10 274.4 ± 68.75 480.0 ± 121.8
CBDL + TUDCA therapeutic 8 246.3 ± 52.54 p = 0.095 413.4 ± 94.49
Data are represented as mean ± SD. *** p < 0.001: CBDL vs. sham. ALT = alanine aminotransferase; AST = aspartate
aminotransferase; TUDCA = tauroursodeoxycholic acid.
2.4. Treatment with TUDCA Reduces CBDL-Induced CHOP and Pro-Apoptotic Markers
In order to explore whether TUDCA exerts its beneficial effect on liver damage and fibrosis
through a reduction in pro-apoptotic UPR signaling, UPR-induced CHOP expression and gene and
protein expression of different pro-apoptotic markers after TUDCA treatment was studied. Western
blot analysis confirmed the induction of the pro-apoptotic transcription factor CHOP at 6 weeks after
CBDL and demonstrated reduced CHOP expression when TUDCA was given preventively (Figure 4a).
Preventive supplementation with TUDCA also significantly reduced mRNA levels of caspase 3 and
both preventive and therapeutic TUDCA treatment reduced cleaved caspase 3 and cleaved caspase 12
protein levels, compared to the CBDL controls (Figure 4b,c). TNFRsf1 expression was only decreased in
the preventive setting whereas FADD was significantly lower following the preventive and therapeutic
TUDCA treatments. Although an increased trend was observed in the CBDL and therapeutic TUDCA
group, the anti-apoptotic Bcl2, was not significantly altered after the CBDL or TUDCA treatment
(Figure 4b). No effect of TUDCA, neither preventively nor therapeutically, was seen on caspase 1 gene
expression in CBDL mice nor on NLRP3 levels (Figure 4d,e).
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Figure 4. Treatment with TUDCA reduces CBDL-induced CHOP and pro-apoptotic markers.
(a) Representative Western blot of CHOP on whole liver lysates. β-Tubulin was used for normalization.
Quantification of CHOP blot compared toβ-tubulin bands. Samples of three to five mice per group were
mixed for blotting; (b) Real-time qPCR analysis of pro-apoptotic genes caspase 3 and 12, TNFRSf1a,
FADD and Bcl2. Data are presented as mean ± SD. * p < 0.05, ** p < 0.01, *** p < 0.001; (c) Western
blot and quantification of cleaved caspase 3 and cleaved caspase 12 on whole liver lysates. β-Tubulin
was used for normalization. One to two samples per group were loaded with one sample consisting
of a mixture of two mice; (d) Real-time qPCR analysis of pro-pyroptotic marker caspase 1. Data are
presented as mean ± SD; (e) Western blot of NLRP3 on whole liver lysates. Quantification of NLRP3
was normalized to total protein load. Three samples per group were loaded with one sample consisting
of a mixture of two mice, so a total of six mice were analyzed.
3. Discussion
3.1. CBDL Induces Hepatic Unfolded Protein and Pro-Apoptotic Response
Cholestatic liver disease is a major cause of liver fibrosis, which is triggered by hepatic cell death.
It has been shown in different in vitro models that toxic bile acids, such as deoxycholic acid and
glycochenodeoxycholic acid, cause ER stress and activation of the UPR [6–8,30]. In later studies,
UPR activation has been investigated in different in vivo mouse models for cholestasis, which led
to conflicting results [9,12,31,32]. However, none of these studies explored the UPR at different
stages during early onset and progression of cholestatic liver disease. Therefore, we investigated
the kinetics of hepatic UPR activation and the mode of associated hepatic cell death in a mouse
model of cholestasis-induced liver fibrosis. In accordance with Mencin et al. and Tamaki et al. [12,31],
we observed no increase in the UPR markers XBP1u and XBP1s (IRE1 pathway) and peIF2α and
ATF4 (PERK pathway). GADD34 was in reased starting from week 3 at the mRNA level, however,
no significant differences in protein levels could be detected. Interestingly, we d onstrated
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gradually increasing levels of CHOP during the progression of liver fibrosis, which is one of the
main UPR downstream effectors able to induce hepatic apoptotic and/or pyroptotic cell death when
overexpressed [14]. Indeed, in case of excessive ER stress, CHOP promotes apoptosis through reduced
expression of the anti-apoptotic protein Bcl-2, with subsequent Ca2+ influx into the cytoplasm [33].
Through m-Calpain, pro-caspase 12 is activated by cleavage, which further drives the caspase
cascade [33]. Sequential activation of caspases plays a central role in the execution phase of apoptosis,
in which caspase 3 is the final common executor of both the intrinsic and extrinsic apoptotic pathway.
In the intrinsic pathway, mitochondrial permeabilization causes cytochrome c release, which activates
caspase 9 and in turn caspase 3. In the extrinsic pathway, caspase 3 is activated by caspase 8 which
is upstream bound and activated by FADD, which is bound to death receptors such as TNFR,
forming the death-inducing signaling complex. In the present study, we demonstrate increased
(cleaved) caspase 3 and 12, FADD and TNFRsf1a expression in fibrotic mice, indicative for the
occurrence of apoptotic cell death during the initiation and progression of biliary liver damage and the
development of fibrosis [34–37]. In addition, activation of CHOP is known to stimulate transcription
of pro-caspase 1 and 11, which become activated upon cleavage and activated by NLRP3, the most
important inflammasome [14]. Active caspase 1 and 11 in turn lead to apoptosis, through caspase 3,
but also to pyroptosis, a programmed form of cell death, characterized by DNA damage, cell lysis
and active IL-1β and IL-18 release [14]. Recently, the combination of CHOP-induced apoptosis and
NLRP3 inflammasome-mediated pyroptosis has been demonstrated to be involved in the pathogenesis
of experimental non-alcoholic steatohepatitis, which was successfully counteracted by treatment
with TUDCA [14]. In our study, increased gene expression of caspase 1 in CBDL mice could be
demonstrated, without, however, any change in NLRP3 protein levels, suggesting the absence of
NLRP3 inflammasome-mediated pyroptosis. Summarized, these findings point towards a central role
of CHOP-induced pro-apoptotic pathways in liver disease due to biliary etiology.
3.2. Treatment with TUDCA Reduces Liver Damage and Liver Fibrosis through Modulation of CHOP and Its
Pro-Apoptotic Response
The chemical chaperone TUDCA, the hydrophilic taurine-conjugated form of UDCA, is known
for its cytoprotective capacities of reducing ER stress and apoptotic cell death [15,20,29,30,38]. Since
we demonstrated that CHOP-induced pro-apoptotic pathways are involved in cholestatic liver
damage and fibrosis, and as TUDCA is known to be able to modulate these pathways in other
diseases [25,27,39], we investigated its therapeutic potential to impede liver fibrosis in the CBDL
mouse model. Importantly, both preventive and therapeutic treatment with TUDCA led to a significant
reduction in the degree of liver fibrosis, which was accompanied by an improving trend for ALT and
AST levels. These findings are in line with previous research which demonstrated that CHOP knockout
mice develop less fibrosis [12]. A recent small double-blind randomized trial evaluated the therapeutic
efficacy of TUDCA (750 mg daily) in liver cirrhosis, using UDCA as a parallel control, with a follow-up
period of six months. They concluded that TUDCA therapy is safe and appears to be more effective
than UDCA in improving biochemical parameters [40]. Our study evaluated the effect of TUDCA
in a long term cholestasis mouse model, whereas other studies often study the effect during early
cholestasis [41,42].
Lastly, we suggest that TUDCA indeed exerts its beneficial effect on liver damage and fibrosis
through alleviating CHOP-induced apoptotic cell death, as treatment with TUDCA led to decreased
CHOP expression and reduced levels of the pro-apoptotic markers caspase 3 and 12, TNFRsf1a
and FADD.
In conclusion, this study indicates that CHOP-mediated apoptotic cell death contributes to the
development of cholestasis-induced liver fibrosis and that treatment with TUDCA has a beneficial
effect on liver fibrosis in this model of biliary fibrosis, which might, at least in part, be the result of its
ER stress-reducing and anti-apoptotic properties. In this way, TUDCA might represent a therapeutic
strategy for the treatment of biliary liver disorders.
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4. Materials and Methods
4.1. Animals
Male 7-week-old Swiss and Sv129 mice, purchased from Harlan (Horst, The Netherlands) and
Iffa Credo (Brussels, Belgium), were housed in the animal facility of the Faculty of Medicine and
Health Sciences, Ghent University, Ghent, Belgium, and acclimatized under controlled conditions for
one week prior to the experiments. They received care in accordance with Federation for Laboratory
Animal Science Associations (FELASA) guidelines and the national guidelines for animal protection.
The animal protocols used in this work were evaluated and approved by the Ethical Committee of
Experimental Animals at the Faculty of Medicine and Health Sciences, Ghent University, Belgium,
(ECD 13/12 approved on 29 April 2013 and ECD 14/67 approved on 3 November 2014).
4.2. Induction of Secondary Biliary Fibrosis
Secondary biliary fibrosis was induced by common bile duct ligation (CBDL) at the age of eight
weeks, as described previously [29]. In brief, under isoflurane (Isoflo®, Abbott, Louvain-la-Neuve,
Belgium) inhalation anaesthesia, a midline abdominal incision was made and the common bile duct
was isolated and ligated with two knots of a non-resorbable suture (Silkan® 5/0, Braun Aesculap,
Tuttlingen, Germany). The first ligature was made below the junction of the hepatic ducts and the
second was made above the entrance of the pancreatic duct. The common bile duct was resected
between the two ligatures after which the abdomen was closed by suturing the abdominal muscle and
skin in two separate layers. Control mice were sham-operated; the common bile duct was isolated but
not ligated.
4.3. Kinetics of Hepatic UPR and Cell Death in Cholestasis-Induced Liver Fibrosis
In order to study the hepatic UPR and cell death during the time course of biliary fibrosis following
CBDL, male Swiss mice were euthanized on a weekly basis, for six consecutive weeks, starting at
week 1 after surgical induction (6 sham and 6 CBDL groups, 7–14 animals in each group). At sacrifice,
liver samples were immediately harvested into liquid nitrogen and kept at −80 ◦C for protein and
mRNA extraction. A portion was fixed in 4% formaldehyde for 24 h and imbedded in paraffin for
histological analysis.
4.4. Preventive and Therapeutic Study with Tauroursodeoxycholic Acid
The therapeutic potential of TUDCA in CBDL mice was studied in both a preventive and
therapeutic study. For the preventive study, male Sv129 CBDL and sham mice received 10 mg/kg/day
TUDCA (Calbiochem, Overijse, Belgium) in their drinking water, starting one week before surgical
induction till the moment of euthanasia. In the therapeutic setting, TUDCA (10 mg/kg/day) was
added to the drinking water, starting 14 days after surgical induction till euthanasia. Control CBDL
and sham mice received normal drinking water. This makes a total of five groups, a sham group
with TUDCA, a sham group without TUDCA, a CBDL control group without TUDCA treatment,
a preventive CBDL group and a therapeutic CBDL group (6–10 animals/group, Table 1). Six weeks
after sham or CBDL surgery, retro-orbital blood was taken under ketamine (100 mg/kg, Ceva santé,
Brussels, Belgium) and xylazin (10 mg/kg, Kela, Sint-Niklaas, Belgium) anesthesia after which the
animals were euthanized by cervical dislocation. Liver samples were collected as described above.
4.5. Evaluation of Liver Fibrosis
The degree of liver fibrosis was scored quantitatively with CellˆD software (version 3.4, Olympus,
Berchem, Belgium) on Sirius red-stained liver sections. A minimum of ten fields per liver section per
mouse were blindly evaluated and scored by two independent researchers (AP and SR).
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4.6. qPCR
RNA was extracted from 20 mg of frozen liver tissue preserved in RNA-later (Ambion, Thermo
Fisher, Ghent, Belgium), according to the manufacturer’s guidelines (Rneasy Mini Kit, Qiagen,
Venlo, The Netherlands) and measured for purity and quantity with spectrophotometry (Nanodrop,
Thermo Scientific, Waltham, MA, USA). cDNA was made out of one microgram of mRNA by
reverse transcription using the iScript cDNA synthesis kit (BioRad, Temse, Belgium) according to
the manufacturer’s instructions. Diluted cDNA was subjected to 45 cycles of quantitative PCR
amplification using SYBR Green mix (Sensimix, Bioline Reagents Ltd., London, UK) and 2 µM of each
primer. A two-step program was run on a LightCyclerR 480 (Roche, Vilvoorde, Belgium). Melting
curve analysis confirmed primer specificities. All reactions were run in duplicate and normalized to
reference genes that showed stable expression in all samples (GAPDH, SDHA, HMBS and HPRT).
The double ∆Cq method was used for processing of qPCR data in which data were compared to the
PBS control group. The PCR-efficiency of each primer pair was calculated using a standard curve of
reference cDNA. Amplification efficiency was determined using the formula 10−1/slope − 1. The primer
set sequences are listed in Table S1.
4.7. Western Blotting
Total protein extract was obtained by homogenizing tissue in RIPA buffer (PBS, 0.5% NP-40,
0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate, 5.5% β-glycerophosphate, 1 mM
dithiothreitol and complete protease and phosphatase inhibitors (Roche Diagnostics, Vilvoorde,
Belgium)). The total protein yield was determined using Bradford reagent (Biorad, Temse, Belgium)
and 30 µg protein was fractionated by SDS-PAGE. Protein lysates from multiple mice per group were
pooled and transferred to a nitrocellulose membrane which was subsequently blocked for 1 h with 5%
BSA, incubated overnight at 4 ◦C with primary antibodies in blocking buffer (Table S2), followed by
1 h incubation at room temperature with horse radish peroxidase-conjugated secondary antibodies
(goat-anti rabbit sc2004, Santa Cruz, Heidelberg, Germany or goat anti-mouse sc2005, Santa Cruz).
Clarity western ECL substrate (Biorad, Temse, Belgium) was used to visualize the proteins. GAPDH
and β-tubulin were used as loading control proteins or total protein load was used for normalization.
4.8. Statistical Analysis
Data analysis was performed using GraphPad (GraphPad Software Inc., San Diego, CA, USA)
and SPSS 21 (IMB Corp, Armonk, NY, USA). Differences between groups were calculated using
t-test (for two groups) or one-way ANOVA analysis with Sidak’s correction (for multiple groups)
for normally distributed data. For non-parametric data, multiple groups were compared using the
Kruskal-Wallis test with Dunn’s post hoc test. Reported p-values were two-sided and considered
significant when lower than 0.05.
5. Conclusions
Our data indicate that TUDCA has a beneficial effect on liver fibrosis in a mouse model of
cholestatic liver disease, and suggest that this effect might, at least in part, be attributed to decreased
hepatic CHOP and pro-apoptotic signaling.
Supplementary Materials: Supplementary materials can be found at www.mdpi.com/1422-0067/18/1/214/s1.
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